Metabolic disorders Flashcards
Insulin: MoA, indications, contraindications, side effects
Insulin is secreted by pancreatic beta cells in response to elevated blood glucose. It acts to modulate glucose absorption from the blood, therefore lowering blood glucose levels.
Generally, it increases anabolic activity (e.g. glycogen/protein/lipid synthesis) and decreases catabolic acitivity (e.g. glycogenolysis, lipolysis) - as energy stores are plentiful.
Indications: T1DM and T2DM which is resistant to other antidiabetic medications
Side effects: Weight gain, hypoglycaemia, lipodystrophy at the injection site
Sulphonylureas: MoA, indications, contraindications, side effects
MoA: Increase insulin secretion from pancreatic beta cells
Indications:
- 2nd line for T2DM who cannot tolerate metformin or can be used in addition to metformin when needs esculate
- Short acting formulations have decreased risk of hypoglycaemia
Contraindications:
- Cause weight gain → not best choice for overweight patients
- Caution in mild-moderate renal impairment as can cause hypoglycaemia
- Severe CV comorbidity
Side effects:
Metformin: MoA, indications, contraindications, side effects
MoA: Enhance the effect of insulin. Activate AMP kinase
Indications:
- Obese patients (as do not cause weight gain)
- Do not cause hypoglycaemia
Contraindications:
- Renal impairment - increased risk of lactic acidosis
Side effects:
- GI effects: Diarrhoea, nausea, vomiting
Meglitinide analogues: MoA, indications, contraindications, side effects
MoA: Enhance insulin secretion from pancreatic beta cells
Indications:
Contraindications:
- Severe renal or hepatic impairment
Side effects:
- Risk of hypoglycaemia
- Weight gain
Thiazolindiediones: MoA, indications, contraindications, side effects
e.g. pioglitazone
MoA: Activate PPAR-gamma, changing gene expression, and causing insulin like effects
- Enhances glucose ultilsation
- Reduces hepatic glucose output
- Increases skeletal muscle glucose transporters
Indications:
- 2nd line option when metformin cannot be used
- Can be used in combination with other drugs if esculating treatment is required
Contraindications:
- Heart failure
- Liver failure
Side effects: !RISKS!
- Increases CV risk
- Increased risk of bladder cancer
- Weight gain
- Risk of bone fractures (osteoporosis)
Dipeptidylpeptidase-4 inhibitors (DPP-4i or Gliptins): MoA, indications, contraindications, side effects
MoA: Inhibit GLP-1 degradation which leads to increased glucose-dependent insulin secretion
Indications:
- 2nd line treatment, for when metformin cannot be tolerated
- Should be used in place of thiazolindiediones (pioglitazone) when further weight cause would cause/exacerbate problems associated with high body weight
Contraindications:
- Liver failure
- Moderate/severe renal failure
Side effects:
- GI complaints
- Pancreatitis
Glucagon-like peptide-1 agonists (GLP-1 or incretins): MoA, indications, contraindications, side effects
MoA: Stimulate the GLP-1 receptor, stimulating insulin release
*Given SC
Indications:
- 3rd line option - when metformin and 2 other oral drugs are not tolerated/effective/contraindicated
Contraindications:
- GI mobility disorders
Side effects:
- Nausea
- Pancreatitis
- Increased risk pancreatic cancer
Sodium-glucose co-transporter-2 inhibitors (SGLT-2): MoA, indications, contraindications, side effects
MoA: Cause glycosuria through inhibition of the renal SGLT-2 transporter in the PCT
Indications:
- Can be used as monotherapy is metformin is inappropriate/not tolerate
- Can be used in combination if treatment needs esculating - preferred use
- Does NOT cause weight gain
Contraindications:
- Age restrictions apply
- If used in combination with insulin/other diabetic drugs then can stimulate insulin secretion. Insulin dose may need adjustment
Side effects:
- Increased risk of DKA
- Increased risk of UTI and yeast infections (more sugar for bacterial growth)
- Polyuria and dehydration
DDP-4, GLP-1, insulin and glucagon relationship diagram
*AIDS UNDERSTANDING OF MECHANISMS*
Outline the guidance for treatment of T2DM
(flow chart)
Describe how blood pressure might be controlled in a diabetic patient
- Target BP = < or equal to 140/80 mmHg if there are no additional complications
- < or equal to 130/80 mmHg if kidney/eye/cerebrovascular complications are present
- Monitor BP at least annually and provide diet/lifestyle advice
- ACEi first line for most - usual NICE hypertension guidelines
- Calcium channel blockers are first line for women of child bearing potential
Describe the pharmocological strategies for the prevention of diabetic nephropathy
- Annual testing for microalbuminuria, urinary protein and serum creatinine
- ACEi (or ARB) given to diabetic patients with nephropathy that is causing proteinuria/microalbuminuria
- NOTE: ACEis can potentiate the hypoglycaemic effects of insulin and oral antidiabetic drugs
Describe lipid management in diabetic patients
Patients with diabetes are at higher risk of developing cardiovascular disease
CV risk can be assessed using:
- Weight
- BP
- Lipids
- Smoking
- Hx of CV disease
- Microalbuminuria
Atorvastatin 20mg is offered for the primary prevention of CVD with a QRISK score > 10 %
HMG CoA reductase inhibitors: MoA, indications, contraindications, side effects
MoA: Inhibit hepatic cholesterol synthesis through inhibition of HMG-CoA reductase. Induce LDL receptor expression leading to decreased LDL levels and elevated HDL levels
Indications:
- First line for hypercholesterolemia
- Patients with atherosclerotic CVD (coronary heart disease, stroke, peripheral vascular disease)
Contraindications:
- Pregnancy and breast feeding
- Active liver disease
- Muscular disease
Side effects:
- GI effects
- Headache
- Hepatic toxicity (CytP450 mediated degradation)
-
Muscle toxicity - check CK levels for elevation if muscle pain is experienced
- Rhabdomyolysis may occur, increasing the risk of AKI
Fibrates: MoA, interactions, contrainteractions, side effects
MoA: Activates PPAR-alpha increasing lipoprotein lipase activity. ↓ LDL and TGs, ↑ HDL
Indications:
- Second line for hyperlipidaemia
Contraindications:
- Hepatic impairment
- Renal insufficiency
- Gall bladder disease
Side effects:
- Dyspepsia
- Cholelithiasis
- Myopathy